Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 23, Issue 8, Pages 1085-1091Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458516674566
Keywords
Multiple sclerosis; neurodegeneration; biomarker; beta-amyloid; tau
Categories
Funding
- Italian Ministry of Health
Ask authors/readers for more resources
Background: Neurodegeneration plays a major role in determining disability in multiple sclerosis (MS) patients. Hence, there is increasing need to identify reliable biomarkers, which could serve as prognostic measure of disease progression. Objectives: To assess whether cerebrospinal fluid (CSF) tau and -amyloid (A) levels were altered in newly diagnosed MS patients and correlated with disability. Moreover, we investigated whether these CSF biomarkers associate with macroscopic brain tissue damage measures. Methods: CSF A and tau levels were determined by enzyme-linked immunosorbent assay in CSF samples from 48 newly diagnosed MS patients, followed-up clinically for 3years by recording their Expanded Disability Status Scale score at 6-month intervals, and 45 controls. All patients underwent magnetic resonance imaging at baseline and at the end of follow-up to quantify their lesion load (LL). Results: CSF A levels were significantly reduced in patients compared to controls (p<0.001). Lower CSF A levels at baseline were a disability predictor at 3-year follow-up (p=0.009). CSF tau levels correlated with T2- and T1-LL (p<0.001). Conclusion: CSF A reduction is a promising biomarker of neurodegeneration and may predict patients' clinical outcome. Therefore, CSF A should be considered as a potential biomarker of prognostic value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available